Next Financial Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Next Financial Group’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-358	Closed	-$15K	–	2434
2020 Q3	$15K	Buy	+358	New	+$15.7K	﹤0.01%	1515
2020 Q2	–	Sell	-358	Closed	-$16K	–	1958
2020 Q1	$16K	Buy	358 +46	+15%	+$2.31K	﹤0.01%	1373
2019 Q4	$19K	Sell	312 -3	-1%	-$179	﹤0.01%	1554
2019 Q3	$18K	Hold	315	–	–	﹤0.01%	1496
2019 Q2	$18K	Hold	315	–	–	﹤0.01%	1507
2019 Q1	$16K	Hold	315	–	–	﹤0.01%	1017
2018 Q4	$13K	Buy	315 +115	+58%	+$5.93K	﹤0.01%	1272
2018 Q3	$14K	Buy	+200	New	+$15.2K	0.01%	904
2017 Q4	–	Sell	-200	Closed	-$10K	–	1478
2017 Q3	$10K	Buy	+200	New	+$12.1K	﹤0.01%	1230
2017 Q1	–	Sell	-200	Closed	-$16K	–	2340
2016 Q4	$16K	Hold	200	–	–	﹤0.01%	1472
2016 Q3	$14K	Buy	+200	New	+$11.1K	﹤0.01%	1524
2014 Q4	–	Sell	-2,500	Closed	-$32K	–	2404
2014 Q3	$32K	Hold	2,500	–	–	0.01%	1183
2014 Q2	$26K	Buy	+2,500	New	+$28.5K	0.01%	516

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Next Financial Group's EGRX Position: Q4 2020 in Review

Next Financial Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2020, closing a stake of 358 shares — an estimated $15K sold.

Next Financial Group first reported a position in EGRX in Q2 2014 and held it in 13 quarters. The position peaked at $32K in Q3 2014. 166 funds tracked by Wall St. Rank hold EGRX as of Q4 2020.

Next Financial Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Next Financial Group sold 358 Eagle Pharmaceuticals, Inc. shares in Q4 2020, an estimated $15K.
Next Financial Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2014 and held it in 13 quarters.
Next Financial Group's Eagle Pharmaceuticals, Inc. position peaked at $32K in Q3 2014.
166 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2020.

Based on Next Financial Group's 13F filing for Q4 2020, filed 5 Feb 2021.